Mostrar el registro sencillo del ítem
dc.contributor.author
Cardinali, Daniel Pedro
dc.contributor.author
Vigo, Daniel Eduardo
dc.contributor.author
Olivar, Natividad
dc.contributor.author
Vidal, Maria Florencia
dc.contributor.author
Brusco, Herminia Alicia
dc.contributor.other
Engin, Atilia
dc.date.available
2021-08-20T12:15:44Z
dc.date.issued
2015
dc.identifier.citation
Cardinali, Daniel Pedro; Vigo, Daniel Eduardo; Olivar, Natividad; Vidal, Maria Florencia; Brusco, Herminia Alicia; Therapeutical implications of melatonin in Alzheimer´s and Parkinson´s diseases; Springer; 2015; 197-238
dc.identifier.isbn
978-3-319-15630-9
dc.identifier.uri
http://hdl.handle.net/11336/138602
dc.description.abstract
Neurodegenerative diseases like Alzheimer?s disease(AD) and Parkinson's disease (PD) are major health problems, and a growingrecognition exists that efforts to prevent them must be undertaken by bothgovernmental and nongovernmental organizations. In this context, the pinealproduct melatonin has a promising significance because of itschronobiotic/cytoprotective properties. One of the features of advancing age isthe gradual decreas in endogenous melatonin synthesis. A limited number oftherapeutic trials have inicated that melatonin has a potential therapeuticvalue as a neuroprotective drug in the treatment of AD, minimal cognitiveimpairent (which may evolve to AD), and PD. Both in vitro and in vivo, melatoninprevented the neurodegeneration seen in experimental models of AD and PD. Forthese effects to occur, doses of melatonin about two orders of magnitude higherthan those required to affect sleep and circadian rhythmicity are needed. Morerecently, attention has been focused on the development to potent melatoninanalogs with proonged effets which were employed in clinical trials insleep-disturbed or depressed patients in doses considerably higher than thoseemployed for melatonin. In view that the relative potencies of the analogs arehigher that that of the natural compound, clinical trials employing melatoninin the range of 50-100 mg/day are needed to assess its therapeutic validity inneurodegenerative disorders
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Springer
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Melatonin
dc.subject
neurodegeneration
dc.subject
free radicals
dc.subject
oxidative stress
dc.subject
aging
dc.subject
parkinsons disease
dc.subject
Alzheimers disease
dc.subject
mild cognitive impairment
dc.subject
melatonin analogs
dc.subject.classification
Fisiología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Therapeutical implications of melatonin in Alzheimer´s and Parkinson´s diseases
dc.type
info:eu-repo/semantics/publishedVersion
dc.type
info:eu-repo/semantics/bookPart
dc.type
info:ar-repo/semantics/parte de libro
dc.date.updated
2021-03-26T19:58:30Z
dc.journal.pagination
197-238
dc.journal.pais
Estados Unidos
dc.journal.ciudad
New York
dc.description.fil
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
dc.description.fil
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
dc.description.fil
Fil: Olivar, Natividad. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
dc.description.fil
Fil: Vidal, Maria Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina
dc.description.fil
Fil: Brusco, Herminia Alicia. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.springer.com/gp/book/9783319156293
dc.conicet.paginas
378
dc.source.titulo
TryptophanMetabolism: Implications for Biological Processes,Health and Disease
Archivos asociados